Memorial Day: 45% Off Premium Subscription! 🕑 ... >> Memorial Day: 45% Off Premium >>
$0.0098
-0.0009 (-8.41%)
At Close: May 24, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

 09:18am, Tuesday, 16'th Feb 2021
TEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, ha

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

 09:20am, Wednesday, 03'rd Feb 2021
TEL AVIV, Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, an
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE